2020
In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Nanna MG, Granger CB. In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel. Annals Of Internal Medicine 2020, 173: jc44. PMID: 33075264, DOI: 10.7326/acpj202010200-044.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeClopidogrelHumansNetwork Meta-AnalysisPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicTicagrelor
2019
A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization And Cardiovascular Interventions 2019, 96: e102-e109. PMID: 31713326, PMCID: PMC7211549, DOI: 10.1002/ccd.28535.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAtrial FibrillationCoronary ThrombosisDual Anti-Platelet TherapyFemaleFibrinolytic AgentsHemorrhageHumansMalePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeDouble therapyOral anticoagulationAtrial fibrillationTriple therapyAntithrombotic therapyCoronary syndromeCoronary interventionStent thrombosisMajor adverse cardiovascular eventsTriple antithrombotic therapyAdverse cardiovascular eventsDual antiplatelet therapyOptimal antithrombotic therapyGood safety profileRandom-effects modelIschemic outcomesAntiplatelet therapyCardiovascular eventsP2Y12 inhibitorsMedical managementRandomized trialsIntracranial hemorrhageSafety profile
2017
Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina
Bazemore TC, Nanna MG, Rao SV. Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. Journal Of Thrombosis And Thrombolysis 2017, 44: 303-315. PMID: 28730406, DOI: 10.1007/s11239-017-1529-6.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAngina, StableCardiac CatheterizationHemorrhageHumansPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Risk AssessmentConceptsAcute coronary syndromeP2Y12 inhibitorsStable anginaCoronary syndromeCardiac catheterizationCoronary artery bypass graft surgeryArtery bypass graft surgeryAdverse ischemic eventsP2Y12 inhibitor administrationP2Y12 inhibitor pretreatmentAdverse cardiovascular eventsBypass graft surgeryPercutaneous coronary interventionStandard of careCardiovascular eventsGraft surgeryCoronary interventionIschemic eventsInhibitor administrationOperative delayPatientsInhibitor pretreatmentAnginaCatheterizationAppropriate timing